clinical trial · NCT02970318
A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL
Acerta Pharma BV·phase3·active not recruiting·n = 310
Chronic Lymphocytic LeukemiaAcalabrutinib (ACP-196)RituximabIdelalisibBendamustine
brief summary
This study is designed to evaluate the efficacy of acalabrutinib compared with rituximab in combination with idelalisib or bendamustine in previously treated subjects with chronic lymphocytic leukemia (CLL).
started
Feb 2, 2017
primary completion
Sep 3, 2021
completion
Oct 1, 2027
last updated
May 11, 2026
official title
A Randomized, Multicenter, Open-Label, Phase 3 Study of Acalabrutinib (ACP-196) Versus Investigator's Choice of Either Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Subjects With R/R Chronic Lymphocytic Leukemia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol